Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 691 to 700 of 2599 total matches.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
that are chemically similar to endogenous hormones
such as estradiol and progesterone.1 FDA-approved
formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Expanded Table: Drugs for Malaria Prophylaxis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
Pediatric
1 adult tab (250/100 mg)
once/day
5-8 kg: ½ ped tab/day (1 ped
tab is 62.5/25 mg)
9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
(Tymlos) and teriparatide
(Forteo) were approved earlier.1 Other drugs used for
treatment ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
of anal blockage
or incomplete evacuation, and a need for manual
maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
.
The first year of treatment costs $88,500.
Its long-term safety is unknown.
Table 1. Pharmacology
Class ...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
, mean spontaneous bowel
movement frequency in week
1 was 5.7-5.9 with the drug and
3.5-4.0 ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota ...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to
tetracyclines.
Pronunciation Key
Omadacycline: oh mad" a sye' kleen Nuzyra: new zye' rah
Table 1 ...
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Inhaled Levodopa (Inbrija) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-B) inhibitor.1
Levodopa is absorbed in the proximal small intestine.
In patients with advanced PD ...
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others).
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-linked
recessive deficiency of coagulation factor VIII that
occurs in about 1 in 5000 male births ...
The FDA has approved emicizumab-kxwh (Hemlibra –
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.